EZH2 and melanoma: Since both USP7 and EZH2 were significantly overexpressed in a subset of patients with solid tumor, and the levels of these two factors were positively correlated, our results suggest that targeting USP7 may provide an effective treatment for patients with melanoma under a biotherapy strategy, furthermore the small-molecule inhibitors of the USP7-EZH2 protein–protein interactions to be developed may be function as potential targets for cancer therapy in the future.